Trial Profile
Assessing Hemophilia A Patient and Physician Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Aug 2022 Status changed from completed to discontinued due to insufficient data.
- 09 Jun 2022 Status changed from recruiting to completed.
- 23 Aug 2019 Planned End Date changed from 30 Apr 2022 to 31 Dec 2021.